Supriya Lifescience Limited

NSE SUPRIYA.NS

Supriya Lifescience Limited Free Cash Flow Yield on January 14, 2025: -0.62%

Supriya Lifescience Limited Free Cash Flow Yield is -0.62% on January 14, 2025, a 63.38% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Supriya Lifescience Limited 52-week high Free Cash Flow Yield is -0.50% on November 22, 2024, which is 19.23% above the current Free Cash Flow Yield.
Supriya Lifescience Limited 52-week low Free Cash Flow Yield is -1.80% on February 02, 2024, which is -187.98% below the current Free Cash Flow Yield.
Supriya Lifescience Limited average Free Cash Flow Yield for the last 52 weeks is -0.99%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NSE: SUPRIYA.NS

Supriya Lifescience Limited

CEO	Dr. Satish Waman Wagh
IPO Date	Dec. 28, 2021
Location	India
Headquarters	207/208 Udyog Bhavan
Employees	448
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.

Key trends

Past 5 years